Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 61

Sort by

Sort Order Select

Journal Articles

Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma

Nirav N. Shah, MD, Ahmad H. Mattour, MD, Leslie L. Popplewell, MD FACP, Charalambos Andreadis, MD, Jason M. Melear, MD, Alexander I. Spira, PhD MD FACP, Jonah Shulman, MD, Sudhir Manda, MD, John M. Burke, MD, Saurabh Chhabra, MD, Jeff P Sharman, MD, Amrita Krishnan, MD, Nina Shah, MD, Clifford DiLea, RPh, Pharm.D., Jason Kuriakose, MBA, Craig Jerome Berman, MD, Shannon L. Matheny, PhD, John P. Leonard, MD, Arturo Molina, MDMS

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-139829

Published: 2020

Journal Articles

A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Ajai Chari, MD, Jesus G. Berdeja, MD, Albert Oriol, Niels W. C. J. van de Donk, MD, Paula Rodriguez, Elham Askari, Maria-Victoria Mateos, MD PhD, Monique C. Minnema, MD PhD, Raluca Verona, PhD, Suzette Girgis, PhD BPharm, MS, Thomas Prior, Brandi W. Hilder, PhD, Jeffery Russell, MD PhD, Jenna D. Goldberg, MD, Amrita Krishnan, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-133873

Published: 2020

Journal Articles

Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Adam D. Cohen, MD, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP, Amrita Krishnan, MD, Rafael Fonseca, MD, Peter A Forsberg, MD, Andrew Spencer, Jesus G. Berdeja, MD, Jacob P. Laubach, MD, Mengsong Li, Voleak Choeurng, Anjali Vaze, Divya Samineni, Teiko Sumiyoshi, James Cooper, Bernard M Fine, Suzanne Trudel

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-136985

Published: 2020

Journal Articles

Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

Amrita Krishnan, MD, Antje Hoering, PhD, Parameswaran Hari, MD MRCP, Rachael Sexton, PhD, Robert Z. Orlowski, MDPhD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-142913

Published: 2020

Journal Articles

Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Alfred L. Garfall, MD, Saad Z. Usmani, MDMBBS,MBA, María-Victoria Mateos, Hareth Nahi, MD PhD, Niels W.C.J. van de Donk, MD PhD, Jesus F. San-Miguel, MD PhD, Albert Oriol Rocafiguera, MD, Laura Rosinol, MD PhD, Ajai Chari, MD, Manisha Bhutani, MD, Lixia Pei, PhD, Raluca Verona, PhD, Suzette Girgis, PhD BPharm, MS, Tara Stephenson, PhD, Jenna D. Goldberg, MD, Arnob Banerjee, MD, Amrita Krishnan, MD

Blood (2020) 136 (Supplement 1): 27.

https://doi.org/10.1182/blood-2020-138831

Published: 2020

Journal Articles

Immune Mediated Mechanisms of Resistance to Daratumumab

Domenico Viola, Ada Dona, Emine Gulsen Gunes, PhD, Estelle Troadec, Xiwei Wu, Sergio Branciamore, Tinisha McDonald, MS, Lucy Ghoda, PhD, Ashish Streatfield, James F Sanchez, PhD, Chatchada Karanes, Myo Htut, Michael Rosenzweig, Jonathan J Keats, PhD, Steven T Rosen, Guido Marcucci, Amrita Krishnan, MD, Flavia Pichiorri, PhD

Blood (2018) 132 (Supplement 1): 3201.

https://doi.org/10.1182/blood-2018-99-117441

Published: 2018

Journal Articles

Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: Final Analysis of a Phase 1 Study

Michael Rosenzweig, Joycelynne Palmer, Ni-Chun Tsai, Ralf Buettner, PhD, Lupe Duarte, Myo Htut, Chatchada Karanes, Nitya Nathwani, MD, Flavia Pichiorri, PhD, Firoozeh Sahebi, Tim Synold, Xiwei Wu, James F Sanchez, Amrita Krishnan, MD, Stephen J Forman, Steven T Rosen

Blood (2018) 132 (Supplement 1): 2007.

https://doi.org/10.1182/blood-2018-99-120042

Published: 2018

Journal Articles

CD84: A Potential Novel Therapeutic Target in Multiple Myeloma

Emine Gulsen Gunes, PhD, Hadas Lewinsky, Domenico Viola, Enrico Caserta, Michael Rosenzweig, Myo Htut, James F Sanchez, PhD, Ralf Buettner, PhD, Guido Marcucci, Jonathan J Keats, PhD, Amrita Krishnan, MD, Steven T Rosen, Idit Shachar, Flavia Pichiorri, PhD

Blood (2018) 132 (Supplement 1): 1924.

https://doi.org/10.1182/blood-2018-99-119655

Published: 2018

Journal Articles

Split First Dose Administration of Daratumumab for the Treatment of Patients with Multiple Myeloma (MM): Clinical Pharmacology and Population Pharmacokinetic (PK) Analyses

Xu Steven Xu, Philippe Moreau, Saad Z. Usmani, MD, Sagar Lonial, MD, Andrzej Jakubowiak, MD PhD, Albert Oriol, MD, Amrita Krishnan, MD, Joan Bladé, MD PhD, Melody Luo, PhD, Yu-Nien Sun, PhD, Liping Zhang, William Deraedt, Ming Qi, MD PhD, Jon Ukropec, PhD, Pamela L Clemens, PhD

Blood (2018) 132 (Supplement 1): 1970.

https://doi.org/10.1182/blood-2018-99-113171

Published: 2018

Journal Articles

Utility of Clinical-Grade Sequencing of Relapsed Multiple Myeloma Patients; Interim Analysis of the Multiple Myeloma Research Foundation (MMRF) Molecular Profiling Protocol

Blood (2017) 130 (Supplement 1): 395.

https://doi.org/10.1182/blood.V130.Suppl_1.395.395

Published: 2017

Journal Articles

MiR- 16 Regulates Crosstalk in NF-κB Inflammatory Signaling between Myeloma Cells and Bone Marrow Macrophages

Jihane Khalife, Domenico Viola, BS, Jayeeta Ghose, Robert Weingart, James F Sanchez, Craig C Hofmeister, MDMPH, Amrita Krishnan, MD, Guido Marcucci, MD, Nadia Carlesso, MD PhD, Enrico Caserta, PhD, Flavia Pichiorri, PhD

Blood (2017) 130 (Supplement 1): 4351.

https://doi.org/10.1182/blood.V130.Suppl_1.4351.4351

Published: 2017

Journal Articles

Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study

Ajai Chari, Saad Z Usmani, MD, Amrita Krishnan, MD, Sagar Lonial, MD, Raymond Comenzo, Kaida Wu, Jianping Wang, Parul Doshi, Brendan M Weiss, MD, Jordan Schecter, Andrzej J. Jakubowiak, MD

Blood (2017) 130 (Supplement 1): 3110.

https://doi.org/10.1182/blood.V130.Suppl_1.3110.3110

Published: 2017

Journal Articles

Copper-64-Labeled Daratumumab As a PET Imaging Tracer for Multiple Myeloma: Potential Use for Minimal Residual Disease Detection

Enrico Caserta, PhD, Junie Chea, Megan Minnix, Domenico Viola, BS, Steven Vonderfecht, Jonathan J Keats, PhD, James F Sanchez, David Colcher, John E. Shively, Amrita Krishnan, MD, Flavia Pichiorri, PhD

Blood (2017) 130 (Supplement 1): 3083.

https://doi.org/10.1182/blood.V130.Suppl_1.3083.3083

Published: 2017

Journal Articles

Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: A Phase 1 Trial

Michael Rosenzweig, MD, Joycelynne M. Palmer, PhD, Ni-Chun Tsai, MS, Ralf Buettner, PhD, Lupe Duarte, Myo Htut, Chatchada Karanes, Nitya Nathwani, Flavia Pichiorri, PhD, Firoozeh Sahebi, George Somlo, Tim Synold, PhD, Xiwei Wu, PhD, Amrita Krishnan, MD, Stephen J. Forman, MD FACP, Steven T. Rosen, MD

Blood (2017) 130 (Supplement 1): 3144.

https://doi.org/10.1182/blood.V130.Suppl_1.3144.3144

Published: 2017

Journal Articles

Therapy-Related ALL Has Distinct Clinical and Pathologic Features Compared to De Novo ALL

Blood (2017) 130 (Supplement 1): 1442.

https://doi.org/10.1182/blood.V130.Suppl_1.1442.1442

Published: 2017

Journal Articles

Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001

Thierry Facon, Sagar Lonial, MD, Brendan M Weiss, MD, Attaya Suvannasankha, MD, Joseph Fay, Bertrand Arnulf, Jainulabdeen J Ifthikharuddin, Carla de Boer, Jianping Wang, Kaida Wu, Ajai Chari, Suzanne Lentzsch, Jordan Schecter, Amrita Krishnan, MD

Blood (2017) 130 (Supplement 1): 1824.

https://doi.org/10.1182/blood.V130.Suppl_1.1824.1824

Published: 2017

Journal Articles

Leflunomide Inhibits c-Myc Signaling and Impairs Myeloma Cell Growth

Ralf Buettner, PhD, Corey James Morales, BA, BS, Enrico Caserta, PhD, Domenico Viola, BS, Joycelynne M. Palmer, PhD, Xiwei Wu, PhD, Nagarajan Vaidehi, PhD, Hongzhi Li, PhD, Tim Synold, PhD, Amrita Krishnan, MD, Flavia Pichiorri, PhD, Michael Rosenzweig, MD, Steven T. Rosen, MD

Blood (2017) 130 (Supplement 1): 4426.

https://doi.org/10.1182/blood.V130.Suppl_1.4426.4426

Published: 2017

Journal Articles

Significant Differences in Stem Cell Transplant Utilization Rates (STUR) of Autologous Hematopoietic Cell Transplant (AHCT) in Multiple Myeloma (MM) Based on Ethnicity without Differences in Efficacy. a CIBMTR Report

Jeffrey R. Schriber, MD, Parmeswaran Hari, MD MRCP, MS, Kwang Woo Ahn, PhD, Mingwei Fei, MS, Amrita Krishnan, MD, Anita D'Souza, MBBS, MD

Blood (2016) 128 (22): 1190.

https://doi.org/10.1182/blood.V128.22.1190.1190

Published: 2016

Journal Articles

Evaluation of Immune Recovery Following Autologous Hematopoietic Cell Transplantation in HIV-Related Lymphoma: Results of the BMT CTN 0803/AMC 071 Trial

Blood (2016) 128 (22): 1346.

https://doi.org/10.1182/blood.V128.22.1346.1346

Published: 2016

Journal Articles

Comparison of Autologous Hematopoietic Cell Transplant (autoHCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), Tandem Autohct with Len Maintenance (TAM) and Autohct with Len Maintenance (AM) for up-Front Treatment of Patients with Multiple Myeloma (MM): Primary Results from the Randomized Phase III Trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 - StaMINA Trial)

Blood (2016) 128 (22): LBA-1.

https://doi.org/10.1182/blood.V128.22.LBA-1.LBA-1

Published: 2016

NARROW

Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma

A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Immune Mediated Mechanisms of Resistance to Daratumumab

Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: Final Analysis of a Phase 1 Study

CD84: A Potential Novel Therapeutic Target in Multiple Myeloma

Split First Dose Administration of Daratumumab for the Treatment of Patients with Multiple Myeloma (MM): Clinical Pharmacology and Population Pharmacokinetic (PK) Analyses

Utility of Clinical-Grade Sequencing of Relapsed Multiple Myeloma Patients; Interim Analysis of the Multiple Myeloma Research Foundation (MMRF) Molecular Profiling Protocol

MiR- 16 Regulates Crosstalk in NF-κB Inflammatory Signaling between Myeloma Cells and Bone Marrow Macrophages

Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study

Copper-64-Labeled Daratumumab As a PET Imaging Tracer for Multiple Myeloma: Potential Use for Minimal Residual Disease Detection

Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: A Phase 1 Trial

Therapy-Related ALL Has Distinct Clinical and Pathologic Features Compared to De Novo ALL

Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001

Leflunomide Inhibits c-Myc Signaling and Impairs Myeloma Cell Growth

Significant Differences in Stem Cell Transplant Utilization Rates (STUR) of Autologous Hematopoietic Cell Transplant (AHCT) in Multiple Myeloma (MM) Based on Ethnicity without Differences in Efficacy. a CIBMTR Report

Evaluation of Immune Recovery Following Autologous Hematopoietic Cell Transplantation in HIV-Related Lymphoma: Results of the BMT CTN 0803/AMC 071 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only